Carregant...

Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial

AIMS: To assess the cardiovascular (CV) safety of oral semaglutide, the first tablet formulation of a glucagon‐like peptide‐1 receptor agonist. MATERIALS AND METHODS: PIONEER 6 is a multinational, randomized, placebo‐controlled, double‐blind trial in patients with type 2 diabetes at high risk of CV...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Diabetes Obes Metab
Autors principals: Bain, Stephen C., Mosenzon, Ofri, Arechavaleta, Rosario, Bogdański, Pawel, Comlekci, Abdurrahman, Consoli, Agostino, Deerochanawong, Chaicharn, Dungan, Kathleen, Faingold, Maria C., Farkouh, Michael E., Franco, Denise R., Gram, Jeppe, Guja, Cristian, Joshi, Pankaj, Malek, Rachid, Merino‐Torres, Juan F., Nauck, Michael A., Pedersen, Sue D., Sheu, Wayne H. ‐H., Silver, Robert J., Tack, Cees J., Tandon, Nikhil, Jeppesen, Ole K., Strange, Mette, Thomsen, Mette, Husain, Mansoor
Format: Artigo
Idioma:Inglês
Publicat: Blackwell Publishing Ltd 2018
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6587508/
https://ncbi.nlm.nih.gov/pubmed/30284349
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.13553
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!